Zervimesine's Phase 3 DLB Pivot: Biomarker Promise Meets Cognitive Efficacy Void

Cognition Therapeutics CEO to Discuss Zervimesine's Phase 3 Plans for DLB Psychosis

Cognition Therapeutics, Inc. announced that its President and CEO, Lisa Ricciardi, will participate in a fireside discussion at the B. Riley Mind, Muscle & Vision Summit on July 16, 2026. During the chat, Ms. Ricciardi will provide updates on the ongoing Phase 2 START study and the planned initiation of a Phase 3 registrational study for zervimesine (CT1812) in dementia with Lewy bodies (DLB) psychosis. The company's lead candidate, zervimesine, has shown promise in Phase 2 trials for DLB and mild-to-moderate Alzheimer’s disease, backed by nearly $200 million in NIH grants.

• Lisa Ricciardi, President and CEO of Cognition Therapeutics, will engage in a fireside discussion with analyst William Wood, Ph.D., at the B. Riley Mind, Muscle & Vision Summit. The event is scheduled for July 16, 2026, at 2:20 PM Eastern Time, taking place at the Intercontinental Boston Hotel. A recording will be made available on the company's investor relations section.
• The discussion will cover the current status of Cognition Therapeutics' ongoing Phase 2 START study, which is evaluating zervimesine (CT1812) in patients with MCI and early Alzheimer’s disease. Additionally, Ms. Ricciardi will detail the planned initiation of a Phase 3 registrational study for zervimesine specifically targeting dementia with Lewy bodies (DLB) psychosis.
• Zervimesine (CT1812) is an investigational once-daily oral therapy that has completed Phase 2 studies in DLB, mild-to-moderate Alzheimer’s disease, and geographic atrophy. Based on strong efficacy signals from the Phase 2 SHIMMER study in DLB, the company plans to advance it into a late-stage trial for DLB psychosis, aiming to address a significant unmet medical need.

Addressing the Unmet Needs in Dementia with Lewy Bodies Psychosis

Dementia with Lewy bodies (DLB) presents a uniquely complex pharmacological challenge: the very agents most commonly employed to manage psychosis are among the most hazardous in this population. Neuroleptic sensitivity — a hallmark feature of DLB — severely constrains the therapeutic toolkit available to clinicians, necessitating a careful risk-benefit calculus at every stage of management.

• Antipsychotic-associated morbidity and mortality risk: Traditional and atypical antipsychotics can precipitate severe, life-threatening reactions in DLB patients, with evidence suggesting they may double or triple the mortality rate. Serious adverse events including somnolence, sedation, delirium, extrapyramidal symptoms, cerebrovascular events, and rapid cognitive decline are well-documented, making routine antipsychotic use untenable in this population.

• Antidopaminergic agents worsen core DLB symptoms: Antidopaminergic medications — including antipsychotics — are known to exacerbate both motor and neuropsychiatric symptoms, including psychosis and cognition, in DLB patients. This creates a therapeutic paradox in which treating psychosis pharmacologically risks worsening the very symptoms it aims to control.

• Limited and closely monitored alternatives: When antipsychotic use is deemed necessary, low-potency agents or atypical neuroleptics with the least extrapyramidal burden (e.g., quetiapine) are preferred, but these are not universally appropriate due to their own adverse effect profiles, safety concerns, and logistical barriers. Close clinical monitoring — particularly during hospitalization — is mandatory.

• Broader psychotropic tolerability issues: Beyond antipsychotics, psychotropic medications as a class are poorly tolerated in DLB. Commonly reported adverse effects include sedation, disinhibition, depression, falls, incontinence, parkinsonism, and akathisia, further limiting symptom management options.

• Anti-parkinsonian treatments carry neuropsychiatric risk: Therapies targeting the motor features of DLB carry a known propensity to exacerbate neuropsychiatric symptoms, particularly hallucinations, introducing an additional layer of clinical complexity when managing comorbid motor and psychotic symptoms concurrently.

• Weak evidence base for first-line alternatives: Cholinesterase inhibitors — currently recommended as first-line therapy for hallucinations and mental status fluctuations in DLB — have an inconclusive evidence base beyond rivastigmine. In one donepezil study, three of seven patients discontinued therapy prematurely due to insufficient response or adverse events, with only three of seven completing the intended 8-week course.

• End-of-life and caregiver burden: DLB-specific features — including fluctuations, hallucinations, and delusions — disproportionately impact caregiver experiences at end of life. Improved strategies for managing behavioral symptoms in late-stage disease represent a significant unmet need with direct implications for both patient dignity and caregiver wellbeing.

Defining the Patient Population for Zervimesine's Pivotal DLB Trial

Pivotal trials in DLB psychosis have relied on consensus diagnostic criteria to define an enrollable, clinically homogeneous patient population. Data from donepezil trials in DLB — encompassing 273 patients with probable DLB across phase II and phase III studies — illustrate how diagnostic and clinical thresholds shape cohort composition, with meaningful variation observed depending on whether patients were recruited from neurological versus psychiatric centers.

• Diagnostic eligibility based on consensus DLB criteria: Enrolled patients were required to meet consensus diagnostic criteria for probable DLB, anchored by the presence of dementia with marked cognitive fluctuation, visual hallucinations, and parkinsonism onset. REM sleep behavior disorder is now recognised as a core diagnostic feature incorporated into patient selection frameworks.

• Neuroimaging as a diagnostic confirmatory tool: Reduced dopamine transporter (DAT) uptake in the basal ganglia, demonstrated via SPECT or PET imaging, carries high specificity (~90%) for distinguishing DLB from Alzheimer's disease, supporting its use as a confirmatory criterion in trial enrollment.

• Center-dependent variation in enrolled patient characteristics: Patients recruited from neurological centers exhibited higher rates of parkinsonism (91.8% vs. 71.2%), more advanced Hoehn and Yahr stage III disease (55.0% vs. 21.2%), and greater use of concomitant anti-Parkinson medications (24.5% vs. 11.0%) compared to those from psychiatric centers — highlighting how recruitment site can systematically affect cohort profile.

• Neuropsychiatric symptom burden at baseline: Enrolled populations reflected the broad neuropsychiatric burden of DLB, with REM sleep behavior disorder, depression, and delusions each observed in approximately 35–40% of patients, and anxiety present in over half (55.3%), underscoring the symptom heterogeneity within diagnostically eligible cohorts.

Zervimesine's Strategic Leap into DLB Psychosis

The announcement regarding zervimesine (CT1812) marks a pivotal moment for its development, signaling a strategic acceleration into a critical area of unmet need: dementia with Lewy bodies (DLB) psychosis. While the journey for CT1812 has largely been defined by its extensive investigation in Alzheimer's disease (AD), the planned initiation of a Phase 3 registrational study for DLB psychosis represents a significant diversification and a focused effort to address a particularly challenging symptom complex. This move is not merely an expansion but a targeted approach to a patient population with limited effective treatment options, where psychosis can profoundly impact quality of life for both patients and caregivers.

CT1812's mechanism of action, as a sigma-2 receptor (S2R) complex allosteric antagonist that prevents and displaces amyloid beta (Aβ) oligomers from neuronal synapses, offers a compelling disease-modifying hypothesis. Research indicates its ability to mitigate synaptotoxicity and restore cognitive function in preclinical models, with early clinical trials showing target engagement through biomarker changes, improved qEEG markers of synaptic function, and even trends towards tissue preservation in AD. However, the path in neurodegenerative drug development is notoriously difficult. Despite these promising mechanistic insights, consistent cognitive efficacy in AD trials has yet to be definitively established, a common hurdle that underscores the complexity of these diseases.

The substantial backing from NIH grants provides a strong foundation for Cognition Therapeutics, Inc., enabling the progression of such ambitious clinical programs. However, the inherent risks of late-stage trials in neurodegeneration remain. The high failure rate in AD drug development, even for candidates with sound scientific rationale, serves as a cautionary tale. Furthermore, while CT1812 has demonstrated a favorable safety profile with generally mild-to-moderate adverse events, the long-term tolerability in a chronic treatment setting for DLB psychosis will be crucial. Nevertheless, by targeting a specific, severe symptom like psychosis in DLB, CT1812 could carve out a unique and impactful niche, potentially offering a novel therapeutic avenue where current options are scarce and often carry significant side effects. This strategic focus could ultimately de-risk the asset and accelerate its path to patients.